Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $90.1 million.

  • Agios Pharmaceuticals' Cash from Investing Activities rose 28323.77% to $90.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $377.2 million, marking a year-over-year increase of 378.14%. This contributed to the annual value of $377.2 million for FY2025, which is 378.14% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Cash from Investing Activities of $90.1 million as of Q4 2025, which was up 28323.77% from $95.6 million recorded in Q3 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Cash from Investing Activities peaked at $1.9 billion during Q1 2021, and registered a low of -$298.1 million during Q2 2021.
  • For the 5-year period, Agios Pharmaceuticals' Cash from Investing Activities averaged around $123.6 million, with its median value being $80.9 million (2022).
  • Data for Agios Pharmaceuticals' Cash from Investing Activities shows a peak YoY increase of 162894.9% (in 2021) and a maximum YoY decrease of 142228.58% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Cash from Investing Activities stood at -$94.4 million in 2021, then soared by 187.85% to $83.0 million in 2022, then rose by 15.14% to $95.5 million in 2023, then crashed by 151.47% to -$49.2 million in 2024, then skyrocketed by 283.24% to $90.1 million in 2025.
  • Its Cash from Investing Activities stands at $90.1 million for Q4 2025, versus $95.6 million for Q3 2025 and $79.0 million for Q2 2025.